FDA OKs Axatilimab in Pediatric/Adult Chronic GVHD
Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.
The recommended dose for those with at least 40 kg is 0.3 mg/kg for up to a maximum of 35 mg. This should be given intravenously over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.
The FDA has approved axatilimab-csfr (Niktimvo) for patients who weigh at least 40 kg with chronic graft-versus-host disease (GVHD) after progression on 2 prior lines of systemic therapy, according to a press release from the agency.1
The approval is based on results from the phase 2 AGAVE-201 trial (NCT04710576), which assed efficacy and safety in patients with relapsed/refractory chronic GVHD. Results were previously presented at the 2023 American Society of Hematology (ASH) Annual Meeting.2
The recommended dose for those with at least 40 kg is 0.3 mg/kg for up to a maximum of 35 mg. This should be given intravenously over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.
“Axatilimab, with its unique mechanism of action, may represent a new therapeutic strategy in chronic GVHD,” Daniel Wolff, MD, PhD, of the University Hospital of Regensburg in Germany, said in a presentation of the data during ASH.
Three dose levels of axatilimab were assessed in adult and pediatric patients. The primary end point was overall response rate (ORR) through cycle 7 day 1, which included complete or partial responses via the 2014 NIH Consensus Development Project on Response Criteria.
In the recommended dosage cohort, the ORR was 75% (95% CI, 64%-84%). The median time to first response was 1.5 months (range, 0.9-5.1), and the median duration of response was 1.9 months (95% CI, 1.6-3.5). Of note, 60% (95% CI, 43%-74%) patients with a response did not die or initiate new systemic therapy for at least 12 months since response.
Topline data from the ASH presentation found an ORR of 74% (95% CI, 63%-83%) in the 0.3 mg/kg every 2 weeks group, 67% (95% CI, 55%-77%) at 1.0 mg/kg every 2 weeks, and 50% (95% CI, 39%-61%) at 3.0 mg/kg every 4 weeks.
Common adverse effects included laboratory abnormalities such as increased aspartate aminotransferase, infection (pathogen unspecified), increased alanine aminotransferase, and decreased phosphate.
References
- FDA approves axatilimab-csfr for chronic graft-versus-host disease. News release. FDA. August 14, 2024. Accessed August 14, 2024. https://shorturl.at/Iqnno
- Wolff D, Cutler C, Lee SJ, et al. Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201). Blood. 2023;142(suppl 1):1. doi:10.1182/blood-2023-186963
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib
November 16th 2024David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.
